Dr. Robert M. Rossi, M.D.
Maternal-Fetal Medicine (High-Risk Pregnancy) (Maternal & Fetal Medicine Physician)
At a glance
- Medical school
- University of South Florida College of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of South Florida College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Maternal & Fetal Medicine Physician primary
OH license 35127898
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Maternal-Fetal Medicine (High-Risk Pregnancy) per capita by county →
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $121 in total to this clinician.
| Novo Nordisk Inc | $121 |
|---|
| Food and Beverage | $121 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $28,840 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.